

Contents

Contributors iii

Preface v

CHAPTER I Preventive Cardiology: Risk Factors for Coronary Artery Disease and Primary and Secondary Prevention 1

Christopher P. Cannon, Benjamin A. Steinberg,
and Alexander C. Fanaroff

CHOLESTEROL AND LIPIDS 1

Epidemiology 1

ACC/AHA Guidelines 3

Drugs 3

Bile Resins (e.g., Cholestyramine, Colestipol) 3

Fibric Acid Derivatives (e.g., Gemfibrozil,

Fenofibrate) 5

Cholesterol Absorption Inhibitors 5

3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase

Inhibitors (Statins) 6

Primary Prevention Trials 7

Secondary Prevention Trials 8

Combined Primary and Secondary Prevention

Trials 8

Early Statin Initiation Trials 9

Raising HDL Cholesterol 10

Niacin 10

Cholesterol Ester Transfer Protein Inhibitors 11

DIET AND VITAMINS 11

Special Diets 11

Alcohol 13

LIFESTYLE FACTORS 13

Obesity 13

Exercise 14

Smoking 15

METABOLIC SYNDROME 15

DIABETES 16

HYPERTENSION 18

Epidemiology 18

Etiology 18

Diagnosis 18

Treatment 20

Nonpharmacologic 20

Pharmacologic 20

Target Blood Pressure 22

NONMODIFIABLE RISK FACTORS 22

Family History 22

Age 22

Gender 22

Genetic Markers 23

HORMONAL STATUS AND HORMONAL THERAPY 23

INFLAMMATION 24

C-Reactive Protein 24

Homocysteine and B Vitamins 25

Lipoprotein-associated Phospholipase A2 25

Infections and Cardiovascular Disease 26

ANTIPLATELET DRUGS FOR PRIMARY AND SECONDARY PREVENTION 27

Aspirin 27

Primary Prevention Trials 27

Secondary Prevention Trials 27

Clopidogrel 29

REFERENCES 30

General Articles 30

Lipids and Cholesterol 31

Guidelines 31

Epidemiology 32

Primary Prevention 34

Early Trials 34

Statins in Primary Prevention 35

Combination Therapy in the Statin Era 37

Secondary Prevention 38

Placebo-controlled Trials 38

Intensive- versus Standard-dose Statin Regimens in Stable CAD 41

Early Statin Initiation in ACS 42

Combined Primary and Secondary Prevention Trials 44

Primary and Secondary Prevention Trials in Patients with Comorbidities	45
Meta-analyses and Noncholesterol Effects of Statins	46
HDL-raising Therapies	48
Niacin	48
CETP Inhibitors	50
Meta-analyses and General Studies	52
Novel Classes of Lipid-lowering Agents	52
Antioxidants, Vitamins, Fish Oil, Chelation, and Hormones	54
Observational Studies	54
Clinical Trials	55
Meta-analyses	60
Diet	61
Observational Studies	61
Clinical Trials	62
Alcohol	64
Lifestyle	64
Guidelines and General Articles	64
Obesity and Weight Loss	67
Exercise	70
Smoking	72
Epidemiology	72
Smoking Cessation	74
Metabolic Syndrome and Diabetes	74
Epidemiology	74
Treatment	76
Hypertension	80
Epidemiology and Risk Factors	82
Studies of Treatment	82
Nonpharmacologic Therapies	82
Medical Therapy	84
Diabetes and Hypertension	92
Invasive Therapies	94
Meta-analyses	95
Nonmodifiable Risk Factors	97
Age and Genetics	97
Inflammation	98
C-Reactive Protein	98
Homocysteine and B Vitamins	100
Observational Studies	100
Trials and Meta-analyses	102

Lipoprotein-associated Phospholipase A ₂ (Lp-PLA ₂)	103
Infections and Cardiovascular Disease	104
Antibiotic Trials	104
HIV-related Cardiovascular Risk	104
Miscellaneous	105
Antiplatelet Drugs for Primary and Secondary Prevention	106
Primary Prevention	106
Secondary Prevention	107
General Review Articles and Meta-analyses	108

CHAPTER 2 Coronary Revascularization and Percutaneous Procedures 110

Christopher P. Cannon, Benjamin A. Steinberg, and Justin M. Dunn

CORONARY ANGIOGRAPHY 110

Indications	110
Flow Grade	110
Stenosis Morphology	111

PERCUTANEOUS CORONARY INTERVENTION 111

Uses and Indications	111
Operator and Hospital Volume	112
Procedural Details	113
Access	113
Contrast Agent	113
Lesion Evaluation	113
Balloon Angioplasty	115
Stenting	116
Medications	117
Aspirin	117
Heparin	117
Low Molecular Weight Heparin	117
Direct Thrombin Inhibitors	118
Thienopyridines/ADP Receptor Antagonists	118
Glycoprotein IIB/IIIA Inhibitors	121
Abciximab (ReoPro)	122
Eptifibatide (Integrilin)	122
Tirofiban (Aggrastat)	123
Applications of PCI	123
Stable Angina	123
Unstable Angina/Non-ST Elevation Myocardial Infarction	124
Acute ST Elevation Myocardial Infarction	124
After Thrombolytic Therapy	124

Stenting versus Percutaneous Transluminal Coronary	
Angioplasty: Major Trials	125
Direct Stenting versus Balloon Predilatation	125
Repeated Intervention	125
Complications	126
Early Complications	126
Later Complications	127
Stent Thrombosis	127
Restenosis	127
Renal Dysfunction	128
Other Postprocedural Complications	128
Treatment and Prevention of Restenosis	129
Drug Studies	129
Radiation Therapy	129
Drug-eluting Stents	129
Directional Atherectomy	131
Rotational Atherectomy	133
Prevention of Distal Embolization	133
Thrombectomy	133
Distal Protection	134
CORONARY ARTERY BYPASS SURGERY	135
Coronary Artery Bypass Surgery versus Medical Therapy	135
Coronary Artery Bypass Surgery versus Percutaneous Coronary	
Intervention	136
Internal Mammary Artery	138
Saphenous Vein Grafts	138
TRANSCATHETER AORTIC VALVE REPLACEMENT	138
Balloon-expandable TAVR	139
Self-expanding TAVR	139
REFERENCES	140
Guidelines and Classification	140
Operator and Hospital Characteristics	141
Catheterization Technique	143
Contrast Agents	144
Lesion Evaluation (Fractional Flow Reserve, Intravascular	
Ultrasound)	146
Comparison of Revascularization with Medical Therapy	147
Stent Studies	149
Early Stent Comparisons	149
Provisional Stenting	151
Direct Stenting	153
Drug-eluting Stents	153

Additional Devices/Techniques	159
Cutting Balloon	159
Atherectomy Studies	161
Radiation Therapy	163
Thrombectomy	167
Distal Protection	168
Adjunctive Pharmacologic Therapy	170
Aspirin	170
Heparin	170
Low Molecular Weight Heparin	171
Thienopyridines	172
Glycoprotein IIB/IIIA Inhibitors	178
Thrombin Inhibitors	184
Special Situations	185
Chronic Total Occlusions	185
Bypass Graft Lesions	186
Small Vessels	187
Diabetes	189
Complications	190
Postintervention CK/CK-MB and Troponin Studies	190
Stent Thrombosis	191
Other Complications	192
Coronary Restenosis	194
Repeat Percutaneous Coronary Intervention for Restenosis after Percutaneous Transluminal Coronary Angiography	194
Effect of Stent Design	196
Drug Studies	197
Coronary Artery Bypass Graft Surgery	201
Coronary Artery Bypass Graft Surgery versus Medical Therapy	202
Coronary Artery Bypass Graft Surgery versus Percutaneous Transluminal Coronary Angiography	203
Graft and Patency	210
Transcatheter Aortic Valve Replacement	212

CHAPTER 3 Unstable Angina/Non-ST Elevation MI 215

Christopher P. Cannon, Benjamin A. Steinberg,
and Matthew W. Sherwood

EPIDEMIOLOGY 215

PATHOPHYSIOLOGY 215

CLASSIFICATION 215

Unstable Angina 215

Non-ST-elevation Myocardial Infarction 217

CLINICAL AND LABORATORY FINDINGS 217

History and Symptoms 217

Electrocardiogram 217

Cardiac Enzymes 217

Creatine Kinase and Creatine Kinase-MB 217

Troponins T and I 218

Myoglobin 218

Estimation of Early Risk at Presentation 218

TREATMENT 220

Aspirin 220

ADP Receptor Antagonists 220

PAR-1 Receptor Antagonists 221

Heparin 221

Low-molecular-weight Heparins 222

Direct Thrombin Inhibitors 223

Factor Xa Inhibitors 224

Glycoprotein IIB/IIIA Inhibitors 224

Intravenous Agents 224

Oral Agents 225

Thrombolytic Therapy 226

Anti-ischemic Medications 226

 β -Blockers 226

Nitrates 226

Calcium Channel Blockers 227

3-Hydroxy-3-methylglutaryl Coenzyme A Reductase

Inhibitors (Statins) 227

Invasive Strategy 227

Coronary Artery Bypass Graft Surgery 229

NONINVASIVE EVALUATION 229

Exercise Treadmill Test 229

Exercise Treadmill Testing with Nuclear Imaging 229

Pharmacologic Stress Testing with Imaging 229

Echocardiography 229

Coronary Computerized Tomography Angiography 230

PROGNOSIS AND BIOMARKERS 230

Unstable Angina 230

Non-ST-elevation Myocardial Infarction 230

Prior Aspirin Use (Aspirin Failures)	230
Electrocardiography	230
Troponin Levels	230
C-Reactive Protein	231
B-Type Natriuretic Peptide	231

REFERENCES 231

Review Articles and Pathophysiology	231
Drugs and Studies	232
Aspirin	232
Thienopyridines	234
PAR-1 Receptor Antagonists	236
Unfractionated Heparin and Warfarin	237
Low-molecular-weight Heparins	239
Anti-ischemic Medications	243
Direct Thrombin Inhibitors	245
Factor Xa Inhibitors	246
Glycoprotein IIB/IIIA Inhibitors	247
Thrombolytics	253
Invasive versus Conservative Management	254
Noninvasive Assessment and Prognosis	258
Clinical or General Analyses	259
Biomarkers	261
Review Articles and Multimarker Studies	261
Troponins	262
High-sensitivity Troponins	263
Inflammatory Markers	263
B-Type Natriuretic Peptide	264
Specific Tests: Angiography, ECG, and Holter	265

CHAPTER 4 ST Elevation Myocardial Infarction 266

Christopher P. Cannon, Benjamin A. Steinberg,
and Justin M. Dunn

EPIDEMIOLOGY 266

PATHOGENESIS 266

Diagnosis	267
Chest Pain	267
Electrocardiography	267
Echocardiography	267
Biomarkers	267

TREATMENT 268

Aspirin 268

P2Y₁₂ Inhibitors 269 β -Blockers 270

Angiotensin-converting Enzyme Inhibitors 271

Aldosterone Antagonism 272

Thrombolytic Therapy 272

Indications for Thrombolysis 273

Contraindications 274

Common Fibrinolytic Agents 274

Streptokinase 274

Tissue Plasminogen Activator 274

Retepase 275

Tenecteplase 275

Prognostic Indicators 276

Percutaneous Coronary Intervention 276

Primary Angioplasty 276

Procedural Volume 277

Primary Angioplasty versus Thrombolysis 277

Rescue Angioplasty 278

Routine PCI (after Thrombolysis) versus Delayed or
Conservative Management 278**Facilitated Percutaneous Coronary Intervention 279**

Cardiogenic Shock 280

Stenting in STEMI 280

Antithrombotic Regimens 281

Heparin 281

Enoxaparin 281

Fondaparinux 282

Direct Thrombin Inhibitors 282

Oral Anticoagulants 283

Intravenous Glycoprotein IIB/IIIA Inhibitors 284

Use in Primary PCI 284

Glycoprotein IIB/IIIA Inhibition Plus Reduced-dose
Thrombolysis 285**Other Therapies 285**

Nitrates 285

Calcium Channel Blockers 285

Antiarrhythmics 286

Magnesium 286

Glucose-Insulin-Potassium 286

Intra-aortic Balloon Pump 287

RIGHT VENTRICULAR INFARCTION 287

Diagnosis 287

Complications 288

Treatment 288

COMPLICATIONS OF STEMI 288

Early 288

Intermediate 289

Late 289

PROGNOSIS AND RISK STRATIFICATION AFTER

MYOCARDIAL INFARCTION 290

Uncomplicated STEMI 290

Complicated Course 291

Specific Tests 292

REFERENCES 293

General Review Articles and Guidelines 293

Epidemiology 293

Pathogenesis 294

Diagnosis 295

Chest Pain and Symptoms 295

Electrocardiography 295

Biomarkers 296

Prehospital and Emergency Department Evaluation 297

Treatment 298

Aspirin 298

P2Y12 Inhibitors 299

β -Blockers 301

Angiotensin-converting Enzyme Inhibitors 304

Reviews and Meta-analyses 304

Studies 305

Thrombolytic Therapy 308

Review Articles and Meta-analyses 308

Thrombolytic Comparative Studies 309

Prehospital Thrombolysis Studies 316

Percutaneous Coronary Intervention 318

Reviews 318

Meta-analyses 318

Primary PCI 319

PCI after Thrombolysis 322

Rescue PCI 328

Operator and Hospital Volumes 329

Stenting in STEMI 329

Antithrombotic Regimens	333
Antithrombins	333
Direct Thrombin Inhibitors	336
Oral Anticoagulants	339
Glycoprotein IIb/IIIa Inhibitors	343
Glycoprotein IIb/IIIa Inhibitors and Reduced-dose Thrombolysis	345
Other Therapies	348
Nitrates	348
Calcium Channel Blockers	348
Antiarrhythmics	350
Magnesium	353
Glucose–Insulin–Potassium	354
Infarct Types	355
Left Ventricular Infarctions	355
Right Ventricular Infarction	357
Treatment of Cardiogenic Shock	357
Percutaneous Assist Devices	358
Assessment and Prognosis	360
Reviews and Meta-analyses	360
Electrocardiography, Arrhythmias, and Conduction Disease	361
Exercise Testing	363
Echocardiography and Other Noninvasive Tests	364
Flow, Vessel Patency, and Angiography	364
Other Prognostic Factors	367
Complications of Myocardial Infarction	369
Arrhythmias, Bundle Branch Block	369
Cardiac Rupture	369
Intracranial Hemorrhage in Thrombolysis	370
Reocclusion, Recurrent Ischemia, and Reinfarction	370
Left Ventricular Thrombi	372
Valvular Damage and Septal Defects	372

CHAPTER 5 Heart Failure 374

Benjamin A. Steinberg and Christopher P. Cannon

EPIDEMIOLOGY 374

HISTORY AND PHYSICAL EXAMINATION 376

ETIOLOGY 377

DIAGNOSTIC TESTING 377

VENTRICULAR ARRHYTHMIAS 445

Immediate Therapy: Automated External Defibrillators 445

Immediate Therapy: Intravenous Amiodarone 446

Secondary Prevention Trials: Drugs versus Implantable

Cardioverter-Defibrillators 446

Primary Prevention Trials: Antiarrhythmic Drugs 449

Primary Prevention Trials: Drugs versus Implantable

Cardioverter-Defibrillators 449

Primary Prevention Trials: Nonischemic Cardiomyopathy

Patients 450

Studies of Emerging Tachyarrhythmia Therapies 451

CARDIAC PACING STUDIES 451

Pacemaker Mode Selection Trials 451

Pacing for Vasovagal Syncope 452

Pacing for Prevention of Atrial Fibrillation 452

Resynchronization Therapy for Congestive Heart Failure 453

REFERENCES 454

Atrial Fibrillation 454

Guidelines 454

Epidemiology 454

Risk Stratification 455

Rate versus Rhythm Control 457

Drug Trials for Rate and Rhythm Control in Atrial
Fibrillation 458

Catheter and Surgical Ablation 467

Catheter Ablation 467

Surgical Ablation 469

Electrical Cardioversion and Pericardioversion

Anticoagulation 470

Long-term Anticoagulation 472

Non-Vitamin K Oral Anticoagulants 477

Nonpharmacologic Stroke Prevention in AF 481

Atrial Fibrillation Prevention after Surgery 481

Ventricular Arrhythmias 482

Guidelines 482

Immediate Therapy: Automated External
Defibrillators 482

Immediate Therapy: Intravenous Amiodarone 483

Secondary Prevention Trials: Drugs versus Implantable

Cardioverter-Defibrillators 484

Primary Prevention Trials: Antiarrhythmic Drugs 485

Primary Prevention Trials: Drugs versus Implantable
Cardioverter-Defibrillators 486

Primary Prevention Trials: Nonischemic Cardiomyopathy
Patients 489

Studies of Emerging Tachyarrhythmia Therapies 490

Cardiac Pacing Studies 491

Guidelines 491

Mode Selection Trials 491

Pacing for Vasovagal Syncope 493

Pacing for Prevention of Atrial Fibrillation 495

Resynchronization Therapy for Congestive Heart
Failure 495

Trial Index 501

Subject Index 513